Cargando…

Letter to editor regarding the systematic review and meta‐analysis by Coleman et al. on the effectiveness of MF59‐adjuvanted seasonal influenza vaccine in older adults

Detalles Bibliográficos
Autores principales:	Yin, J. Kevin, Samson, Sandrine I., Nealon, Joshua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542953/ https://www.ncbi.nlm.nih.gov/pubmed/34342136 http://dx.doi.org/10.1111/irv.12891

Ejemplares similares

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
por: Li, Athena P. Y., et al.
Publicado: (2021)

Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
por: Imran, Mahrukh, et al.
Publicado: (2022)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Response letter regarding the letter to the editors by Brown et al.
por: Taylor, Sylvia, et al.
Publicado: (2016)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years
por: Yin, J. Kevin, et al.
Publicado: (2022)

Letter to the editor regarding the article of Chen et al.
por: Islamoglu, Mehmet Sami, et al.
Publicado: (2022)

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children
por: Kazmin, Dmitri, et al.
Publicado: (2023)

Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine Among Adults ≥65 Years
por: McGovern, Ian, et al.
Publicado: (2023)

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59
por: Ren, Shu-Ting, et al.
Publicado: (2017)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis
por: Coleman, Brenda L., et al.
Publicado: (2021)

Letter to Editor from Dr. Steiner, et al. regarding JVIM_15039
Publicado: (2018)

Hawkins, Coleman
Publicado: (1992)

Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands
por: Wijnans, Leonoor, et al.
Publicado: (2013)

Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59(®)‐adjuvanted influenza vaccine in older adults: Results from three consecutive seasons
por: Panatto, Donatella, et al.
Publicado: (2019)

Response from Dr. Cridge, et al. to Dr. Steiner, et al. letter to editor regarding JVIM_15039
Publicado: (2018)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial
por: Esposito, Susanna, et al.
Publicado: (2020)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Sid Coleman and Erice
por: Zichichi, Antonino
Publicado: (2011)

The complete Coleman Hawkins
Publicado: (1987)

The genius of Coleman Hawkins
Publicado: (1986)

Coleman v. Coldwell
Publicado: (1899)

Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study
por: Rubinstein, F, et al.
Publicado: (2013)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus
por: Decaro, Nicola, et al.
Publicado: (2011)

Letter to the editor: in response to Alstrup et. al.
por: Slagt, Cor, et al.
Publicado: (2019)

Letter to the Editor response: Nygaard et al.
por: Towfic, F., et al.
Publicado: (2017)

Response to the Letter to the Editor by Eberhard et al.
por: Bottomley, Christian, et al.
Publicado: (2017)

Letter to the Editor in Response to Khazanchi et al.
por: Nayak, Aditi, et al.
Publicado: (2021)

Letter to the editor from Pant et al
por: Pant, Shubham, et al.
Publicado: (2021)

Letter to the Editor: In Response to Sarkar et al.
por: Pokhrel, Damodar, et al.
Publicado: (2021)

Reply to Letter to the Editor by Yin et al.
por: Coleman, Brenda L., et al.
Publicado: (2021)

Reply to the letter to the editor by Mungmunpuntipantip et al.
por: Longo, M., et al.
Publicado: (2021)

Letter to the Editor in Response to Zhou et al
por: Troth, Sean, et al.
Publicado: (2021)

Letter to the Editor from Colle et al
por: Colle, Raphael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tm0o65j8fj3k3b6d8ogsj4fli1